在新加坡的门诊诊所实施预防性药物基因组学测试的可行性研究 (IMPT研究)
Fiona Fj Ng1, Rashmi Verma1, Levana Sani1
1NalaGenetics Pte Ltd (NalaGenetics), Singapore, Singapore.
The pharmacogenomics journal
|March 13, 2025
概括
预防性药物基因组学 (PGx) 测试在新加坡的初级保健中是可行的,其中95%的患者具有可操作的遗传变异. 这种方法提高了患者对药物的信心,并改善了临床工作流程.
科学领域:
- 药物基因组学 药物基因组学
- 临床药房 临床药房
- 遗传学 遗传学 是一个
背景情况:
- 在初级保健中,关于预防性药物基因组学 (PGx) 测试的数据有限.
- 在门诊环境中实施PGx服务带来实际挑战,并影响临床工作流程.
- 了解患者和临床医生的看法对于采用至关重要.
研究的目的:
- 评估在新加坡的初级保健门诊部实施预防性PGx检测的可行性.
- 评估与将PGx测试整合到日常护理中的实用性和挑战.
- 确定预防性PGx测试对临床工作流程和患者护理的影响.
主要方法:
- 在新加坡五个门诊诊所进行的前性研究 (2022年10月至2023年8月).
- 招募了21-65岁的患有慢性疾病风险或服用PGx相关药物的患者.
- 使用基于qPCR的面板,对五种药物基因中的21个等位基因变异进行了评估;调查评估了人们的看法.
主要成果:
- 在222名患者中,95%的人至少有一种临床可操作的遗传变异.
- 在接受研究药物治疗的患者中,21.2%的患者根据PGx结果获得了可执行的建议.
- 70%的受访患者报告对药物的信心增加;临床医生指出需要监管清晰度.
结论:
- 预防性PGx测试是可行的,并在新加坡的初级保健中提供临床益处.
- 可操作变体的高流行率支持常规实施.
- 解决监管和保险问题的关键是为了更广泛的采用.
相关概念视频
Pharmacogenetics and Pharmacogenomics: Overview
253
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
253
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenetics of Drug Metabolism: Overview
194
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
338
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
338
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121


